NephroDI Therapeutics is a pharmaceutical company headquartered in Seattle, Washington, focused on developing and commercializing drugs to treat concentration disorders of the kidney. The company's lead program is NDI-5001, a novel kidney-targeted small molecule AMPK activator being developed as a potential first-in-class treatment of Congenital Nephrogenic Diabetes Insipidus.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/20/24 | undisclosed | Venture |
Sound Bioventures | undisclosed |
